Exploratory analysis of psychiatric-related utilization and costs associated with paliperidone ER compared with other oral atypical antipsychotics using pharmacy claims from an administrative database

References

• Keeping Care Complete: International Caregivers Survey. Woodbridge, VA: World Federation for Mental Health, 2006
   Google Scholar
• Sajatovic M. Bipolar disorder: disease burden. Am J Manag Care 2005;11:S80-84
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-897
   PubMed Web of Science ®Google Scholar
• Kessler RC, Walters EE. Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey. Depress Anxiety 1998;7:3-14
   PubMedGoogle Scholar
• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105
   PubMed Web of Science ®Google Scholar
• McMorris BJ, Downs KE, Panish JM, et al. Workplace productivity, employment issues, and resource utilization in patients with bipolar I disorder. J Med Econ 2010;13:23-32
   PubMedGoogle Scholar
• Keeping Care Complete: International Psychiatrists Survey. Woodbridge, VA: World Federation for Mental Health, 2008
   Google Scholar
• Baillargeon J, Binswanger IA, Penn JV, et al. Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry 2009;166:103-109
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003;73:123-131
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Frank E, Grochocinski VJ, et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002;63:120-125
   PubMed Web of Science ®Google Scholar
• Grant BF, Stinson FS, Hasin DS, et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005;66:1205-1215
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Konarski JZ, Soczynska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv 2006;57:1140-1144
   PubMed Web of Science ®Google Scholar
• Folsom DP, Hawthorne W, Lindamer L, et al. Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. Am J Psychiatry 2005;162:370-376
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627
   PubMed Web of Science ®Google Scholar
• Naismith SL, Longley WA, Scott EM, et al. Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study. BMC Psychiatry 2007;7:32
   PubMed Web of Science ®Google Scholar
• Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression. JAMA 2003;289:3135-3144
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-1475
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-1129
   PubMed Web of Science ®Google Scholar
• Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001;19:483-495
   PubMed Web of Science ®Google Scholar
• Simpson GM. Atypical antipsychotics and the burden of disease. Am J Manag Care 2005;11:S235-241
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-449
   PubMed Web of Science ®Google Scholar
• Lasser RA, Bossie CA, Gharabawi GM, et al. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005;77:215-227
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Sutton VK, Hamilton SH, et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003;23:582-594
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
   PubMed Web of Science ®Google Scholar
• Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-1222
   PubMed Web of Science ®Google Scholar
• Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-1056
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69:817-829
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Hsiao JK. Interpreting the results of the CATIE study. Psychiatr Serv 2006;57:139
   PubMedGoogle Scholar
• Rosenbaum PR, Rubin DR. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
   Web of Science ®Google Scholar
• Jing Y, Kim E, You M, et al. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. J Med Econ 2009;12:104-113
   PubMedGoogle Scholar
• Kim E, Maclean R, Ammerman D, et al. Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis. Clin Ther 2009;31:836-848
   PubMed Web of Science ®Google Scholar
• HCUP CCS. Healthcare Cost and Utilization Project (HCUP). December 2009. Agency for Healthcare Research and Quality, Rockville, MD. Available at: www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp
   Google Scholar
• Vera-Llonch M, Delea TE, Richardson E, et al. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health 2004;7:569-584
   PubMed Web of Science ®Google Scholar
• Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin 2008;24:3341-3355
   PubMed Web of Science ®Google Scholar
• Chen L, McCombs JS, Park J. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia. Value Health 2008;11:34-43
   Google Scholar
• Bounthavong M, Okamoto MP. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. J Eval Clin Pract 2007;13:453-460
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, et al. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 2004;3:11
   PubMedGoogle Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc 2009;7:4
   PubMedGoogle Scholar
• Barbui C, Lintas C, Percudani M. Head-to-head comparison of the costs of atypical antipsychotics: a systematic review. CNS Drugs 2005;19:935-950
   Google Scholar
• Geitona M, Kousoulakou H, Ollandezos M, et al. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry 2008;7:16
   PubMedGoogle Scholar